- Psychosis:
- IM 12.5-25mg every 3-6 weeks
- Increase by 12.5-25mg every 3-6 weeks
- Max: 100mg/dose
Injection: 25mg/mL
- Not to be given IV
Phenothiazine
It selectively antagonizes dopamine D2 receptors
- Anticholinergic effects
- Sedation
- Weight gain
- Erectile dysfunction
- Oligomenorrhea/ amenorrhea
- Extrapyramidal symptoms
- Nausea
- Anorexia
- Dyspepsia
- Headache
- Peripheral edema
- Depression
- Leukopenia
- Hyperprolactinemia
- Gynecomastia
- Galactorrhea
- Impotence
- Hypersensitivity to class/components
- Comatose patients
- Subcortical brain damage
- Severe CNS depression
- Severe respiratory depression
- Severe bone marrow depression
- Blood dyscrasia
- Hepatotoxicity
WARNING
Patients with dementia-related psychosis are at increased risk for death
- Saquinavir
- Yohimbe
- Potassium salts
- Ibutilide
- Indapamide
- Metrizamide
- Pentamidine
- Pimozide
- Procainamide
- Quinidine
- Sotalol
- Amisulpride
- Disopyramide
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Contraindicated |
Schedule | Controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Fluanxol | 0.5mg | Tablet | 100’s | Janssen Pharma | Phillips Therapeutics |
Fluanxol | 3mg | Tablet | 100’s | Janssen Pharma | Phillips Therapeutics |
Fluanxol Depot | 20mg/mL | Injection | 1’s | Janssen Pharma | Phillips Therapeutics |
Fluanxol Depot | 40mg/2mL | Injection | 1’s | Janssen Pharma | Phillips Therapeutics |